Product
Antihistamine
10 clinical trials
17 indications
Indication
Breast NeoplasmsIndication
Esophageal squamous cell carcinomaIndication
Mucopolysaccharidosis Type 1Indication
Relapsing Multiple SclerosisIndication
Multiple SclerosisIndication
Primary ProgressiveIndication
COVID-19Indication
Postexercise HypotensionIndication
Influenza vaccineIndication
ACE InhibitorsIndication
Atrial FibrillationIndication
Antihistamine AllergyIndication
AmantadineIndication
Bladder CancerIndication
MedulloblastomaIndication
EpendymomaIndication
NSCLCClinical trial
A Phase 1 Study of H3B-6545 in Japanese Women With Estrogen Receptor-positive, HER2 Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06BStatus: Recruiting, Estimated PCD: 2026-11-07
Clinical trial
A Phase III, Single Arm, Cross-over, Multicenter Clinical Trial to Compare Efficacy and Safety of P046 (Laronidase; CinnaGen) Versus Laronidase (Aldurazyme®; Genzyme, BioMarin) in Patients With Mucopolysaccharidosis Type I (MPS I)"Status: Completed, Estimated PCD: 2023-08-12
Clinical trial
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase InhibitorsStatus: Not yet recruiting, Estimated PCD: 2028-09-12
Clinical trial
An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple SclerosisStatus: Completed, Estimated PCD: 2023-04-11
Clinical trial
Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 InfectionStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Histamine as a Molecular Transducer of Adaptation to ExerciseStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 InfectionStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)Status: Completed, Estimated PCD: 2022-08-01
Clinical trial
Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and EpendymomaStatus: Active (not recruiting), Estimated PCD: 2029-10-30